HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Christopher F O'Brien Selected Research

valbenazine

1/2021A long-term, open-label study of valbenazine for tardive dyskinesia.
1/2019Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference.
12/2018Characterizing Treatment Effects of Valbenazine for Tardive Dyskinesia: Additional Results From the KINECT 3 Study.
1/2018Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials.
11/2017The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.
9/2017Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine.
1/2017KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
1/2017Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
1/2017Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
1/2017Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Christopher F O'Brien Research Topics

Disease

12Tardive Dyskinesia
01/2021 - 10/2015
5Mood Disorders (Mood Disorder)
12/2018 - 01/2017
5Schizophrenia (Dementia Praecox)
12/2018 - 01/2017
4Psychotic Disorders (Schizoaffective Disorder)
12/2018 - 01/2017
3Dyskinesias (Dyskinesia)
01/2019 - 10/2015
2Mental Disorders (Mental Disorder)
01/2018 - 01/2017
2Movement Disorders (Movement Disorder)
01/2017 - 10/2015
1Psychomotor Agitation (Akathisia)
11/2017
1Parkinsonian Disorders (Parkinsonism)
11/2017
1Congenital adrenal hyperplasia due to 21 hydroxylase deficiency
03/2016
1Spasm (Spasms)
11/2002
1Contracture
11/2002
1Stroke (Strokes)
11/2002
1Cerebral Palsy (Spastic Diplegia)
11/2002
1Pain (Aches)
11/2002

Drug/Important Bio-Agent (IBA)

12valbenazineIBA
01/2021 - 10/2015
7Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)IBA
01/2019 - 01/2017
4Antipsychotic Agents (Antipsychotics)IBA
12/2018 - 10/2015
1Dopamine (Intropin)FDA LinkGeneric
01/2018
1Dopamine Receptors (Dopamine Receptor)IBA
01/2017
1Corticotropin-Releasing HormoneIBA
03/2016
1Pharmaceutical PreparationsIBA
10/2015
1Botulinum Toxins (Botulinum Toxin)IBA
11/2002

Therapy/Procedure

1Aftercare (After-Treatment)
01/2017
1Therapeutics
11/2002
1Activities of Daily Living (ADL)
11/2002